Germany’s Merck KGaA is in advanced talks for a potential acquisition of SpringWorks Therapeutics, a U.S. biopharmaceutical ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

(Reuters) -Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by ...

TD Cowen downgraded Merck (MRK) to Hold from Buy with a price target of $100, down from $121. The firm says its Buy thesis “broke down” with Gardasil’s challenges in China. It is ...

Merck KGaA (MKGAY) confirms “advanced discussions” with Springworks Therapeutics (SWTX) regarding a potential acquisition. “Merck also confirms that no legally binding agreement has been ...

The global Microcarriers market, valued at US$2.03 billion in 2023, is forecasted to grow at a robust CAGR of 8.0%, reaching US$2.08 billion ...

The global Microcarriers market, valued at US$2.03 billion in 2023, is forecasted to grow at a robust CAGR of 8.0%, reaching US$2.08 billion in 2024 and an impressive US$3.05 billion by 2029. Market ...

The life sciences industry is experiencing an identity crisis. The life sciences industry has a unique social contract with the public, given its role in developing and commercializing therapies ...

KGaA (MRK:GR) (OTC: MKGAF) stock from Overweight to Equalweight and reduced its price target from EUR190.00 to EUR160.00. The downgrade reflects a shift in the investment firm's perspective on the ...

Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases ...

Life Sciences Industry Report - Part 7 The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems. Digital ...

In October, Merck took up an option on the personalised RNA-based cancer vaccine with an upfront payment of $250 million as part of a collaboration first agreed in 2016 and expanded in 2018.